Cargando…
Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway
Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032361/ https://www.ncbi.nlm.nih.gov/pubmed/29904013 http://dx.doi.org/10.3390/ijms19061770 |
_version_ | 1783337490456772608 |
---|---|
author | Li, Yanwei Gong, Qian Guo, Wenjin Kan, Xingchi Xu, Dianwen Ma, He Fu, Shoupeng Liu, Juxiong |
author_facet | Li, Yanwei Gong, Qian Guo, Wenjin Kan, Xingchi Xu, Dianwen Ma, He Fu, Shoupeng Liu, Juxiong |
author_sort | Li, Yanwei |
collection | PubMed |
description | Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of mouse mammary epithelial cells (mMECs). In vivo, LPS were injected to the tetrad pair of nipples for establishing mouse mastitis, and then tested the effect of farrerol on histopathological changes, inflammatory response and activation degree of protein kinase B (AKT), nuclear factor-kappa B p65 (NF-κB p65), p38, extracellular regulated protein kinase (ERK1/2). In vitro, the mMECs were incubated by farrerol for 1 h following by stimulating with LPS, and then the inflammatory response and the related signaling pathways were detected. The in vivo results found that farrerol could improve pathological injury of mammary gland, attenuate the activity of myeloperoxidase (MPO), inhibit the production of pro-inflammatory mediators and the phosphorylation of AKT, NF-κB p65, p38 and ERK1/2. The in vitro results also found farrerol inhibited inflammatory response and the related signaling pathways. Collectively, this study revealed that farrerol inhibits the further development of LPS-induced mastitis by inhibiting inflammatory response via down regulating phosphorylation of AKT, NF-κB p65, p38, and ERK1/2. These findings suggest that farrerol may be used as an anti-inflammatory drug for mastitis. |
format | Online Article Text |
id | pubmed-6032361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60323612018-07-13 Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway Li, Yanwei Gong, Qian Guo, Wenjin Kan, Xingchi Xu, Dianwen Ma, He Fu, Shoupeng Liu, Juxiong Int J Mol Sci Article Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of mouse mammary epithelial cells (mMECs). In vivo, LPS were injected to the tetrad pair of nipples for establishing mouse mastitis, and then tested the effect of farrerol on histopathological changes, inflammatory response and activation degree of protein kinase B (AKT), nuclear factor-kappa B p65 (NF-κB p65), p38, extracellular regulated protein kinase (ERK1/2). In vitro, the mMECs were incubated by farrerol for 1 h following by stimulating with LPS, and then the inflammatory response and the related signaling pathways were detected. The in vivo results found that farrerol could improve pathological injury of mammary gland, attenuate the activity of myeloperoxidase (MPO), inhibit the production of pro-inflammatory mediators and the phosphorylation of AKT, NF-κB p65, p38 and ERK1/2. The in vitro results also found farrerol inhibited inflammatory response and the related signaling pathways. Collectively, this study revealed that farrerol inhibits the further development of LPS-induced mastitis by inhibiting inflammatory response via down regulating phosphorylation of AKT, NF-κB p65, p38, and ERK1/2. These findings suggest that farrerol may be used as an anti-inflammatory drug for mastitis. MDPI 2018-06-14 /pmc/articles/PMC6032361/ /pubmed/29904013 http://dx.doi.org/10.3390/ijms19061770 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Yanwei Gong, Qian Guo, Wenjin Kan, Xingchi Xu, Dianwen Ma, He Fu, Shoupeng Liu, Juxiong Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway |
title | Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway |
title_full | Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway |
title_fullStr | Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway |
title_full_unstemmed | Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway |
title_short | Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway |
title_sort | farrerol relieve lipopolysaccharide (lps)-induced mastitis by inhibiting akt/nf-κb p65, erk1/2 and p38 signaling pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032361/ https://www.ncbi.nlm.nih.gov/pubmed/29904013 http://dx.doi.org/10.3390/ijms19061770 |
work_keys_str_mv | AT liyanwei farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway AT gongqian farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway AT guowenjin farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway AT kanxingchi farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway AT xudianwen farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway AT mahe farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway AT fushoupeng farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway AT liujuxiong farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway |